– CAMCEVI™ is the first ready-to-inject sterile formulation of leuprolide mesylate for subcutaneous injection that comes in a pre-filled syringe with no mixing required –
DURHAM, N.C. , March 31, 2022 /PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care therapies, announced today the U.S. launch of CAMCEVI™ (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults. Accord BioPharma is heading distribution in the U.S. The U.S. Food and Drug Administration approved the New Drug Application (NDA) of CAMCEVI from Foresee Pharmaceuticals on May 25, 2021 .
CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide mesylate for subcutaneous injection that comes in a pre-filled syringe with no mixing required. In an open-label, single-arm study of 137 adults who received 42mg of CAMCEVI on Day 0 and Week 24, CAMCEVI offered consistent testosterone suppression to castrate levels after the initial injection, from Week 4 to Week 48.1 CAMCEVI should not be used in patients with hypersensitivity to GnRH or GnRH analogs due to possible anaphylactic reactions.1 The most common adverse reactions (≥10%) occurring during a median follow-up duration of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.1
Eligible patients prescribed CAMCEVI will have access to support services, such as commercial copay assistance solutions, patient assistance programs, and a nurse-staffed clinical hotline that provides on-demand answers to questions from patients or their care team. These patient support services are uniquely designed to meet the needs of our patient population, helping remove barriers to therapy and supporting patients throughout their healthcare journey with CAMCEVI. To learn more, visit www.camcevihcp.com.
Additionally, Accord BioPharma offers healthcare professionals access to AccordConnects™, a mobile application designed to help healthcare practices manage in-practice inventory of CAMCEVI. The app enables healthcare practices to scan barcodes to accurately log CAMCEVI physical inventory count, project future product inventory requirements, run inventory stock and utilization reports, and allows for forward and backward traceability to locate product.
"The U.S. launch of CAMCEVI demonstrates our commitment to going beyond the biology of medicine, to see disease from a patient's perspective and develop high-quality therapies that enhance the overall treatment experience," said Chrys Kokino , President of U.S. BioPharma at Accord BioPharma.
Important Safety Information: CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy. Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. Patients should be monitored for cardiovascular disease and according to current clinical practice. Androgen deprivation therapy may prolong the QT interval. Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Monitor serum levels of testosterone following injection of CAMCEVI. Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women. The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremities.
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patient's perspective and develop high-quality therapies that impact patient's lives. The founders of Accord BioPharma have dedicated their time, passion, and resources to focusing on specialty care and treatments, proactively developing better ways of working, and delivering enhanced therapies. For more information, Visit AccordBioPharma.com.
1. CAMCEVI. Prescribing Information. Accord BioPharma; May 2021 .
Contact: Nuvan Dassanaike Senior Vice President Digital and Marketing Strategy & Operations Cell: (412) 553-9955
View original content to download multimedia:https://www.prnewswire.com/news-releases/accord-biopharma-announces-us-launch-for-camcevi-leuprolide-injection-emulsion-for-the-treatment-of-advanced-prostate-cancer-in-adults-301515068.html
Clovis Oncology Inc (NASDAQ: CLVS) announced positive topline data from the monotherapy arm of Phase 3 ATHENA-MONO trial of Rubraca (Rucaparib) as first-line maintenance treatment in ovarian cancer. Rubraca achieved the primary endpoint of significantly improved progression-free survival (PFS) compared with placebo (20.2 months vs. 9.2 months). The median PFS for the HRD-positive patient population treated with rucaparib was 28.7 months vs. 11.3 months among those who received a placebo. The med
Yahoo Finance's Anjalee Khemlani details Dr. Anthony Fauci's addressing the latest COVID-19 strain, the Omicron BA.2 subvariant, changing health guidelines, and progress in the latest vaccines getting FDA approval.
Vertex is one step closer to getting its new pain pill approved, which could substitute for opioids that are highly addictive.
Betting on turnarounds in companies that others are too scared to touch can be a successful strategy for some investors. Farsighted investors who recognize the enduring potential of a business -- even during its most vulnerable hours -- can sometimes (but of course, not always) get outsize returns if they're right. One biotech stock that could be ripe for exactly that kind of play is Cassava Sciences (NASDAQ: SAVA), which is down over 70% from its high in July of last year as a result of a parade of misfortunes.
By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update TNX-1500 to Enter Phase 1 Clinical Trial in 2H22 Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) recently highlighted new preclinical data for TNX-1500 showing long-term rejection free graft survival in heart and kidney allografts in non-human primates (NHPs). The studies were conducted at Massachusetts General
The company dosed the first patient in a phase 1/2 study of its gene therapy candidate targeting a rare eye disease.
Vladimir Putin was visited by a thyroid cancer doctor 35 times at his luxury Black Sea retreat, and regularly takes steroids, according to documents revealing the autocrat’s state of health for the first time.
Almost every day, Ark Invest buys at least a handful of innovation-heavy stocks for its collection of exchange-traded funds. Ark Invest founder and CEO Cathie Wood has a lot of confidence in the genomic revolution, and in two companies in particular. Hardly a day in March has gone by without Wood making purchases of Adaptive Biotechnologies (NASDAQ: ADPT), Burning Rock Biotech (NASDAQ: BNR), or both.
The biotech firm was barely a decade old when the pandemic hit. "We essentially had to build the company overnight," HR chief Tracey Franklin tells Fortune.
"Your genitals should smell like genitals, not 'Sunday Morning Sunshine.'"View Entire Post ›
Shares of Clovis Oncology Inc. soared 40.0% in premarket trading on Thursday after the company said its drug, Rubraca, improved survival when used as a maintenance treatment for women with ovarian cancer. The data comes from a double-blind, placebo-controlled, Phase 3 clinical trial that enrolled 538 women. Clovis said it plans to seek approval for Rubraca in the E.U. and the U.S. this year as first-line maintenance treatment for women with advanced ovarian cancer regardless of their biomarker s
Publix might be a regional grocer, but its reach is quite mighty: The supermarket chain has more than 1,000 store locations spread throughout Southeastern states like Florida, Tennessee, and Virginia, and more than 82 percent of the shoppers who visit its stores are repeat-buyers, according to Numerator. That means the retailer must be doing something right. But Publix could experience some backlash from these loyal shoppers soon because of a recent decision made by the company. The grocer just
Photo Illustration by Luis G. Rendon/The Daily Beast/Getty/Austin Fire Department/U.S. Department of Veterans AffairsA teenage neo-Nazi accused of torching a Texas synagogue last Halloween suffers from “a myriad of mental health issues,” but his parents—one of whom is a well-respected physician now serving as a high-ranking Veterans Affairs official—never got him the treatment he desperately needed, according to a federal magistrate judge.Further, the judge said, after doctors at a leading psych
There have been nearly 80 million total cases of COVID-19 in the US, and almost 975,000 deaths, according to stats from the "New York Times." Over the past two years, there have been times when it felt like everyone I knew was contracting the highly contagious virus, especially during the initial spike in cases, as well as during the surges caused by the delta and omicron variants.
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update HyBryte™ NDA Anticipated in 2022 Soligenix, Inc. (NASDAQ:SNGX) previously completed a Phase 3 clinical trial of HyBryte™ (SGX301, synthetic hypericin) in patients with cutaneous T cell lymphoma (CTCL). The FLASH ( F luorescent L ight A ctivated S ynthetic H ypericin) trial was a randomized, double blind, placebo
U.S. lawmakers moved close to agreeing on a bipartisan compromise to provide a fresh $10 billion to combat COVID-19 on Thursday, a deal that could set up final congressional approval next week.
Shares of IPO stock Amylyx crumbled Thursday after a split FDA committee voted against its experimental ALS treatment.
As Bruce Willis steps away from acting due to aphasia, we profile other celebs who've battled the same condition that affects speech and language.
The MORE act would decriminalize cannabis products at the federal level. The measure now heads to the Senate for consideration.
The U.S. House of Representatives on Friday passed a bill to end the federal ban on marijuana, which has created legal headaches for users and businesses in the states that have legalized it, though the measure was seen as unlikely to pass the Senate. The Marijuana Opportunity Reinvestment and Expungement Act, sponsored by Democratic Representative Jerrold Nadler of New York, which is in the process of legalizing the drug, removes marijuana from the list of controlled substances and eliminates criminal penalties for individuals who grow, distribute or possess it. But the MORE act will need to gain 60 votes in the evenly divided Senate before moving to President Joe Biden's desk for his signature, an outcome widely seen as unlikely given the lack of Republican support for the measure.